ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,867.08
-0.09%
Dow Jones
42,342.24
0.04%
US Dollar vs MXN
20.3254
-0.11%
Brent Oil
72.385
0.00%
Bitcoin
96,477.11
-1.01%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) Noticias

NUVL

Nuvalent (NUVL)

Nuvalent Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:NUVL
FechaHoraFuenteTítuloSímboloCompañía
19/12/202405:30PR Newswire (US)Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
18/12/202415:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/12/202405:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
09/12/202405:30PR Newswire (US)Nuvalent Appoints Grant Bogle to Board of DirectorsNASDAQ:NUVLNuvalent Inc
26/11/202405:52PR Newswire (US)Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
25/11/202415:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NUVLNuvalent Inc
12/11/202405:42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NUVLNuvalent Inc
12/11/202405:30PR Newswire (US)Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/11/202413:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:NUVLNuvalent Inc
18/09/202415:05PR Newswire (US)Nuvalent Announces Closing of Upsized Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
17/09/202415:13Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NUVLNuvalent Inc
17/09/202405:42IH Market NewsInvestors Anticipate Retail Sales Data and Fed Decision; Oil Prices Dip as Investors Weigh U.S. ProductionNASDAQ:NUVLNuvalent Inc
16/09/202421:23PR Newswire (US)Nuvalent Announces Pricing of Upsized Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
16/09/202406:00PR Newswire (US)Nuvalent Announces Public Offering of Common StockNASDAQ:NUVLNuvalent Inc
14/09/202404:00PR Newswire (US)Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development TimelinesNASDAQ:NUVLNuvalent Inc
13/09/202408:53PR Newswire (US)Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655NASDAQ:NUVLNuvalent Inc
09/09/202405:30PR Newswire (US)Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class ProfilesNASDAQ:NUVLNuvalent Inc
29/08/202405:30PR Newswire (US)Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
08/08/202405:30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
22/07/202405:30PR Newswire (US)Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective InhibitorNASDAQ:NUVLNuvalent Inc
16/07/202405:30PR Newswire (US)Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024NASDAQ:NUVLNuvalent Inc
11/07/202415:45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
11/07/202405:30PR Newswire (US)Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific OfficerNASDAQ:NUVLNuvalent Inc
29/05/202405:30PR Newswire (US)Nuvalent to Participate in the 2024 Jefferies Global Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
16/05/202415:01PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655NASDAQ:NUVLNuvalent Inc
09/05/202405:30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/04/202415:30PR Newswire (US)Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
05/03/202415:52PR Newswire (US)Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
27/02/202406:00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NUVLNuvalent Inc
27/02/202405:42Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NUVLNuvalent Inc
 Showing the most relevant articles for your search:NASDAQ:NUVL

Su Consulta Reciente

NYSE
CVX
Chevron
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
BTCUSD
Bitcoin
AMEX
SPY
SPDR S&P 500
CCOM
US500
US 500
AMEX
XLV
Health Care Select Sector
COIN
DOGEUSD
Dogecoin
SPI
SP500
S&P 500
PM
XAUUSD
Gold vs US Dollar
USOTC
BNPQY
BNP Paribas (QX)
COIN
ETHUSD
Ethereum
FX
EURUSD
Euro vs US Dollar
NYSE
NKE
Nike
NYSE
KO
Coca Cola
COIN
XRPUSD
Ripple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados